Stem Cell Based Therapies for Glaucoma

Jayaram, Hari; Becker, Silke; Limb, G. Astrid

doi:10.5772/21726

Cited by 2 publications

(1 citation statement)

References 125 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to being human cells, they can be produced with the genetic background of afflicted patients, which can be a uniquely powerful tool for studying human cell biology, disease phenotype, and drug or environmental responses. Additionally the prospect of using PSC derived RGCs for cell replacement therapy is a component of an ultimate curative goal for advanced disease (Cooke and Meyer, 2015; Jayaram et al, 2011; Pearson and Martin, 2015). …”

Section: Introductionmentioning

confidence: 99%

Temporal expression of CD184(CXCR4) and CD171(L1CAM) identifies distinct early developmental stages of human retinal ganglion cells in embryonic stem cell derived retina

Aparicio

Hopp

Choi

et al. 2017

Experimental Eye Research

View full text Add to dashboard Cite

Human retinal ganglion cells (RGCs) derived from pluripotent stem cells (PSCs) have anticipated value for human disease study, drug screening, and therapeutic applications; however, their full potential remains underdeveloped. To characterize RGCs in human embryonic stem cell (hESC) derived retinal organoids we examined RGC markers and surface antigen expression and made comparisons to human fetal retina. RGCs in both tissues exhibited CD184 and CD171 expression and distinct expression patterns of the RGC markers BRN3 and RBPMS. The retinal progenitor cells (RPCs) of retinal organoids expressed CD184, consistent with its expression in the neuroblastic layer in fetal retina. In retinal organoids CD184 expression was enhanced in RGC competent RPCs and high CD184 expression was retained on post-mitotic RGC precursors; CD171 was detected on maturing RGCs. The differential expression timing of CD184 and CD171 permits identification and enrichment of RGCs from retinal organoids at differing maturation states from committed progenitors to differentiating neurons. These observations will facilitate molecular characterization of PSC-derived RGCs during differentiation, critical knowledge for establishing the veracity of these in vitro produced cells. Furthermore, observations made in the retinal organoid model closely parallel those in human fetal retina further validating use of retinal organoid to model early retinal development.

show abstract

Section: Introductionmentioning

confidence: 99%

Temporal expression of CD184(CXCR4) and CD171(L1CAM) identifies distinct early developmental stages of human retinal ganglion cells in embryonic stem cell derived retina

Aparicio

Hopp

Choi

et al. 2017

Experimental Eye Research

View full text Add to dashboard Cite

show abstract

Are nanotechnology and robotics alternatives for therapeutic and theragnostic ophthalmic applications technologies for eye care services

Ospina¹

2013

J. Ocul. Dis. Ther.

View full text Add to dashboard Cite

Objective: To identify new technological advances in biotechnology, nanotechnology and robotics and their application in diagnosis and therapeutics for visual health. Methodology: The systematic review was made in Journal of Engineering, Journal of Biomedical Nanotechnology, NIH Public Access, Investigative Ophthalmology & Visual Science, Intechweb open access journal and books, among others for a total review of 43 articles and 6 books. The databases used were: NLM Catalogue, (NCBI), Scirus, CiteSeer and open access (Intechopen, Hindawi) with the advances in nanotechnology, artificial vision and robotics applied to visual health. Results: Retina implants, ocular memristors, ocular electrodes and chips, digital cameras and smart phone applications for low vision patients are some of the new alternatives in technology for the diagnosis based on biotechnology and nanotechnology and on the several years of job of interdisciplinary and multidisciplinary researchers of different fields to make innovation useful for visual impairment, ocular microbiology and molecular immunodiagnostics. The FDA recently approved the retina implants and this opened a new field to allow converting light signals into electrical signals. On the other hand, in the field of pharmacology, ocular nano-carrier molecules for sustained release of drugs and other devices to vitrectomies are some of the significant health advance studies for the future in visual health. Additionally, in the field of contact lenses and artificial corneas: biopolymers for biosensors have been developed for early detection of keratoconus and systemic diseases. Conclusions: Nanotechnology, biotechnology, robotics and bio-molecular biology are emerging and convergent sciences that when applied to visual sciences will be helpful for the patients, and are an increase in papers on innovation of this field, involving a multidisciplinary team requiring new divulgation in the role and performance of the visual health professionals of the future. To know and divulgate these new technologies is important for continued joint efforts around global education, and to create a database with new keywords, in order to know who and where these innovations are improving around the world, to planning researcher mobility and to include these new valuable technologies in the curriculum of visual health and get the patient safe.

show abstract

Stem Cell Based Therapies for Glaucoma

Cited by 2 publications

References 125 publications

Temporal expression of CD184(CXCR4) and CD171(L1CAM) identifies distinct early developmental stages of human retinal ganglion cells in embryonic stem cell derived retina

Temporal expression of CD184(CXCR4) and CD171(L1CAM) identifies distinct early developmental stages of human retinal ganglion cells in embryonic stem cell derived retina

Are nanotechnology and robotics alternatives for therapeutic and theragnostic ophthalmic applications technologies for eye care services

Contact Info

Product

Resources

About